1 INTRODUCTION {#SEC1}
==============

Gene expression is often profiled for several tissues to get insights into gene function and regulation (Dezso *et al.*, [@B7]; Liu *et al.*, [@B16]; Su *et al.*, [@B20]). In this respect, finding genes that are selectively expressed in a particular tissue is of importance to unravel the biological processes taking place in the particular tissue and to identify candidate biomarkers (Klee, [@B13]; Liang *et al.*, [@B15]; Su *et al.*, [@B20]). It is important to make a distinction between three types of tissue-selectivity \[see Klee ([@B13]) for a review\]: (i) the gene is only expressed in a particular tissue; usually this type of expression is called 'tissue-specific' (Skrabanek and Campagne, [@B19]); (ii) the gene is expressed at approximately the same level in all tissues except one \[called categorical tissue specificity by Schug *et al.* ([@B18])\]; or (iii) the gene is over- or underexpressed in a particular tissue compared with all the other tissues (Kadota *et al.*, [@B10], [@B11]). The latter broadest type of preferential expression in a particular tissue is often called tissue-selective (Greller and Tobin, [@B9]; Liang *et al.*, [@B15]). Note that tissue-specific as defined by Skrabanek and Campagne ([@B19]) is a special case of categorical tissue specificity and that categorical tissue specificity is a special case of tissue-selectivity. In accordance with these different definitions of tissue-selectivity, different methods to find genes with the particular expression profile have been proposed. The remainder of the article focuses on the broadest class of tissue-selectivity, namely relative over- or underexpression in a particular tissue compared with all the other tissues. All methods are explained and illustrated for selective over-expression, but the generalization to selective underexpression is straightforward.

To find tissue-selective genes, we found two approaches in the literature that rely on a firm statistical framework, hereby reducing arbitrary choices to a minimum. A first approach is unsupervised and relies on outlier detection to scan expression profiles for outlying values (Kadota *et al.*, [@B10], [@B11]). The resulting tissue-selective profiles can be selectively expressed in more than one tissue and can be both up- or downregulated in these tissues. A drawback of the method is that it cannot account for biological and technical variation because either all replicate values are included in the analysis (with the likely outcome that only some replicate values will be detected as outlying), or a single representative measure (e.g. average over the replicates) has to be used in the analysis. The second approach is supervised and constructed for the case of replicate arrays for each tissue (Liang *et al.*, [@B15]). It relies on hypothesis testing procedures to test whether a gene is selectively overexpressed in a particular tissue. *t*-tests are used to measure how significant the difference in expression of each of the target tissue--other tissue pairs is and a gene is declared tissue-selective when each of the differences is significant. The problem of multiple testing is accounted for by using the Tukey--Kramer multiple comparison procedure. Although the obtained tissue-selective genes are claimed to have higher expression in the target tissue than in *each of* the other tissues, the statistical procedure used is tailored to find those genes that are significantly higher expressed in the target compared with *at least* one of the other tissues. To understand why this is the case, observe that Tukey--Kramer and other common multiple comparison procedures like Bonferroni and Dunnett (Dunnett, [@B8]) control the chance of wrongfully rejecting the null hypothesis of no significantly different target--other tissue pair against the alternative of *at least one* significantly different pair. What is needed, is a test that controls the chance of wrongfully rejecting the null hypothesis against the alternative of *all* significantly different target--other tissue pairs.

A test that would have the desired alternative hypothesis of significantly higher expression in the target tissue compared with each of the other tissues, was proposed by Berger ([@B3]) and is known as the intersection--union test (IUT; Berger and Hsu, [@B2]). However, the IUT test has two disadvantages. First, it is conservative implying that many tissue-selective genes would be missed; and second, the obtained results are not very informative as the test only indicates whether a gene is tissue-selective or not without any distinction in the degree of tissue selectivity (see also Allison *et al.*, [@B1]). As an alternative, we would like to propose a Bayesian procedure.

In this article, we first briefly describe the IUT and we introduce a Bayesian alternative. Subsequently, both procedures are compared in a simulation study and the Bayesian procedure is used to find the tissue-selective genes for a panel of 22 tissues.

2 METHODS {#SEC2}
=========

2.1 Intersection--union test {#SEC2.1}
----------------------------

Assume some specific gene and a specific target tissue *t*. Let us further denote by *H*~0*j*~ the partial null hypothesis that the gene under study is expressed equally or higher in tissue *j* than in the target tissue. Furthermore, we denote by *H*~1*j*~ the partial alternative that that the gene is expressed higher in the tissue target *t*. Then the gene is selectively upregulated in target tissue *t*, if the compound null hypothesis that *H*~0*j*~ holds for at least one tissue (*j*≠*t*), is rejected against the compound alternative hypothesis that for all tissues (*j*≠*t*) *H*~1*j*~ holds. Using formal notation, the set of compound hypotheses is composed by and . Note that this is different from common multiple comparison procedures where the underlying set of compound hypotheses is that all partial null hypotheses hold (i.e. ) against the alternative that at least one partial null hypothesis can be rejected (i.e. ()). Berger ([@B3]) introduced a procedure to test the composite null hypothesis against the composite alternative (see also Berger and Hsu, [@B2]). A result is declared significant by this test at level α, if it holds that each partial null hypothesis *H*~0*j*~ can be rejected at level α. As proven by Berger, the significance level of his test is less than or equal to the significance level used for each of its implied partial tests.

The IUT can be applied to the problem of finding tissue-selective upregulated genes as follows. For a particular gene, test each target tissue--other tissue pair at the desired significance level (e.g. 0.05) using a suitable test-statistic like the *t*-test. Only when all pairs yield a significant result, the gene is declared selectively overexpressed. Note that to account for the problem of testing multiple genes, the significance level used can be adapted using Bonferonni\'s or Sidak\'s correction. An adaptation to finding underexpressed genes is straightforward by testing the partial null hypothesis that the gene under study is expressed equally or *lower* in tissue *j* than in the target tissue against the partial alternative that the gene is expressed lower in the target tissue. An efficient implementation of this approach in MATLAB or R can be found online (<http://ppw.kuleuven.be/okp/software/BayesianIUT/>).

Often the significance level of the IUT is (much) less than α such that the procedure is conservative (a gene will not be easily declared to be selectively upregulated in the tissue). This yields a very low false discovery rate, however, at the cost of many false negatives. Deng *et al.* ([@B6]) proposed an adjusted IUT for the special case of two independent tests that is less conservative. Note, however, that it is not suitable to find tissue-selective genes (the common target makes that the tests are dependent and usually interest is in comparing the target with more than two other tissues). Another disadvantage of the IUT is that it indicates whether a gene is selectively overexpressed or not, but not to which degree. No distinction is made, for example, at the 0.05 level of significance between a tissue-selective upregulated gene that has *P*-value of 0.03 for each of the target--other tissue pairs and a gene that has *P*-value of 0.0001. The IUT can be made somewhat more informative by reporting the largest *P*-value of the partial tests (Tuke *et al.*, [@B22]), thus focusing only on the least differing target tissue--other tissue pair.

2.2 Bayesian evaluation of the constrained hypothesis {#SEC2.2}
-----------------------------------------------------

In this section, we describe a Bayesian alternative for the IUT to evaluate the hypothesis of tissue-selective overexpression. Note that the procedure will be explained for one gene. The data consist of *i* = 1,..., *N* expression levels *y*~*i*~ for *j* = 1,..., *J* tissues. The total sample size *N* = ∑~*j*~ *N*~*j*~ with *N*~*j*~ denoting the number of replications for tissue *j* which means that *i* is nested in *j*. So, for example, for *j* = 1, *i* = 1,..., *N*~1~, for *j* = 2, *i* = *N*~1~ + 1,..., *N*~1~ + *N*~2~. The model for the expression level is where μ~*j*~ denotes the population mean of tissue *j*, *d*~*ji*~ is 1 if the expression was obtained for tissue *j* and 0 otherwise and ϵ~*i*~ ∼ 𝒩(0, σ^2^). The density of the data for this ANOVA model is where ***y***=\[*y*~1~,..., *y*~*N*~\] and ***d***~*j*~ = \[*d*~*j*1~,..., *d*~*jN*~\].

The goal is to determine the support in the data for two hypotheses: which states that μ~1~ is larger than each of the means in the set {μ~2~,..., μ~*J*~} (the gene is tissue-selective), and Note that *H*~2~ corresponds to *H*~0~ of the IUT. Support in the data will be quantified using the Bayes factor (Kass and Raftery, [@B12]). Using Chib\'s approach (Chib, [@B4]) the Bayes factor of *H*~1~ versus *H*~2~ can be written as: where **θ**=\[μ~1~,..., μ~*J*~\], *h*(·) denotes the prior distribution of the parameters for the hypothesis indicated and *g*(·) the posterior distribution. The dependence of *f*(·) and *g*(·) on ***d***~1~,..., ***d***~*J*~ is left implicit. Note that BF~12~=6 implies that the support in the data for *H*~1~ is six times as large as the support in the data for *H*~2~.

It is convenient to write where *u* refers to *H*~*u*~ : μ~1~,..., μ~*J*~, that is, an unconstrained model. Once a prior distribution has been specified for *H*~*u*~ the prior distribution of *H*~*m*~ for *m* = 1, 2 is obtained via where *I*~**θ**∈*m*~ = 1 if **θ** is in agreement with the constraints of model *m* and 0 otherwise, and *c*~*m*~ is the proportion of *H*~*u*~ in agreement with *H*~*m*~.

The prior distribution of *H*~*u*~ is that is, the prior distribution of each μ~*j*~ is the same. With this specification, and independent of the choice of μ~0~, τ~0~, ν~0~ and σ^*2*^~0~, *c*~1~ = 1/*J* and *c*~2~ = (*J* − 1)/*J*, which makes sense because there are *J* equivalent models in which one of the means is larger than the other means. Using ([7](#M7){ref-type="disp-formula"}) and ([8](#M8){ref-type="disp-formula"}), *BF*~1*u*~ can, for any value of **θ** in agreement with *H*~1~, be written as: where *f*~1~ is the proportion of the unconstrained posterior distribution in agreement with the constraints of *H*~1~ because: Using a similar derivation for *BF*~2*u*~, it is obtained that See Klugkist and Hoijtink ([@B14]) for a more elaborate discussion of the derivation of the Bayes factor for inequality constrained hypotheses in the context of ANOVA. As will be illustrated in [Section 3.1](#SEC3.1){ref-type="sec"}, if the number of means smaller than the target mean increases, the Bayes factor increases in favor of the hypothesis of selective overexpression and if the number of means larger than the target mean increases, the Bayes factor increases in favor of the complement of the hypothesis of selective overexpression. Furthermore, note the following property of the Bayes factor. Consider the situation where all means have the same value. Then the expected value of *f*~1~ = 1/*J* and *f*~2~ = (*J* − 1)/*J*, that is, *BF*~12~ = 1. Stated otherwise, if all means are equal the Bayes factor is neutral with respect to the hypothesis of interest and its complement. According to the Bayes factor one or more means being equal to the mean of the target tissue is neither evidence in favor nor against the hypothesis of selective overexpression.

The only question remaining is the estimation of *f*~1~ because *f*~2~=1 −*f*~1~. Using a very large (but finite) number for τ~0~, any number for μ~0~, ν = −2 and σ^2^~0~ = 0, that is very uninformative priors, the following algorithm renders a sample from the unconstrained posterior distribution of μ~1~,..., μ~*J*~, σ^2^ and an estimate of *f*~1~: Step 1: assign initial values: for *j*=1,..., *J* and , where denotes the sample average for tissue *j*.Step 2: for *j*=1,..., *J* sample μ~*j*~ from *g*(μ~*j*~ ∣ σ^2^, ***y***) which is a normal distribution with mean and variance σ^2^/*N*~*j*~.Step 3: verify whether or not the current values of μ~1~,..., μ~*J*~ are in agreement with the constraints of *H*~1~.Step 4: sample σ^2^ from *g*(σ^2^ ∣ μ~1~,..., μ~*J*~, ***y***) which is a scaled inverse chi-square distribution with degrees of freedom *N*−2 and scale parameter 1/(*N*−2)∑~*i*~(*y*~*i*~−μ~1~*d*~1*i*~−···−μ~*J*~*d*~*Ji*~)^2^.Iterate Steps 2 through 4. The proportion of vectors μ~1~,..., μ~*J*~ sampled in Step 3 in agreement with the constraints of *H*~1~ is an estimate of *f*~1~.

Note that this algorithm has two favorable properties. First, our approach is objective in the following sense: (i) due to the use of vague prior distributions, the posterior is proportional to the likelihood, that is, *f*~1~ and *f*~2~ are completely determined by the data, and (ii) since the prior is the same for each mean, *c*~1~ and *c*~2~ do not depend on the prior. Second, no burn-in is needed because convergence is almost instantaneously as we sample from an inverse normal chi-square distribution and because we initialize the algorithm with the sample average and sample variance. In applications, we used 5000 iterations in the Gibbs sampler. Testing for selective underexpression can be done by adapting the constraints in *H*~1~; on the algorithmic level this only influences Step 3. An efficient implementation of this algorithm in MATLAB or R can be found online (<http://ppw.kuleuven.be/okp/software/BayesianIUT/>).

3 RESULTS {#SEC3}
=========

We compared the performance of the IUT and Bayesian procedure in finding tissue-selective overexpressed genes using simulated and real data. Real data were obtained after robust multichip analysis (RMA) preprocessing and a log~2~ transformation. Because the simulation can be used as a reference for the empirical data, several parameters in the simulation were chosen the same as for these data. These are the number of tissues (22), the number of replications per tissue (three to five), the total number of expression values for a gene (70), the SD per tissue calculated over the replications (*s*=0.04, corresponding to the median SD in the data) and the overall mean expression level (μ = 7.3).

3.1 Simulation {#SEC3.1}
--------------

Here, we compare the performance of the two testing procedures in a controlled setting using simulated data. Two influencing factors are of interest, namely the amount of support in the data and the degree to which the expression differs between the target and other tissues (the so-called effect size; Cohen, [@B5]). First, for the amount of support four levels will be considered: (i) complete support by all 21 tissues to which the target is compared; (ii) one tissue that is neutral, that is, has the same mean as the target tissue, and 20 supporting; (iii) one tissue not supporting and 20 supporting; and (iv) none of the 21 tissues supporting. Second, the effect size δ is manipulated at two levels: one with a considerable overlap of the sampling distributions, δ = 0.5*s* = 0.02, and one with a small overlap δ = 2*s* = 0.08. The data are generated from a normal distribution with SD *s* = 0.04 and mean equal to 7.3 for the target, to 7.3 − δ for a tissue supporting the hypothesis and to 7.3 + δ for a tissue not supporting the hypothesis. Note that the effect sizes used may seem too small for what can be expected from expression data. However, using effect sizes larger than approximately three leads to an almost complete separation of the sampling distributions such that performance of both the IUT and Bayesian approach would be almost perfect.

The results for the simulation are summarized in [Table 1](#T1){ref-type="table"} that reports the proportion of genes for which the data support that they are selectively overexpressed in the target tissue. The panels correspond to different decision rules for tissue-selective overexpression: in the first panel, this is a significant result for the IUT; in the second panel, this is a Bayes factor larger than one (more support for *H*~1~ than for *H*~2~); and in the third panel this is for a Bayes factor larger than 32 (support for *H*~1~ is 32 times larger than the support for *H*~2~). The rows correspond to the four different amounts of support, while the two columns of each panel correspond to the two levels of effect size. Histograms of the log transformed Bayes factor[^1^](#FN1){ref-type="fn"} are shown in [Figure 1](#F1){ref-type="fig"}. These were used to determine the cutoff of 32 (corresponding to a log~2~ value equal to 5). Table 1.Proportion of tissue-selective overexpressed genesIUTBF\> 1BF\> 32δ=0.5*s*δ=2*s*δ=0.5*s*δ=2*s*δ=0.5*s*δ=2*s*Complete support of *H*~1~0.0020.2570.5880.9960.0240.689One tissue neutral w.r.t. *H*~1~0.0020.0430.5680.9410.0200.301One tissue not supporting *H*~1~000.50.2380.0140.002No support at all of *H*~1~000.09000[^2] Fig. 1.Histograms of the log~2~ transformed Bayes factors. (**A**) Complete support of *H*1. (**B**) One tissue neutral with respect to *H*~1~. (**C**) One tissue not supporting *H*~1~. (**D**) None of the tissues supporting *H*~1~. Panels at the left are obtained with a considerable overlap of the sampling distributions, at the right with a small overlap.

Clearly, the IUT is conservative. Even in the most favorable case (complete support, large effect size), only 26% of the genes are declared to be tissue-selective,[^2^](#FN2){ref-type="fn"} corresponding to a false negative rate of 74%. Compare this with the corresponding results for the Bayesian procedure (middle panel of [Table 1](#T1){ref-type="table"}): the majority of the Bayes factors indicate that *H*~1~ is supported, even when the effect size is small. As can be seen in the third row of [Table 1](#T1){ref-type="table"}, this more liberal character of the Bayesian approach leads to many false positive results, but can be solved by requiring that the Bayes factor should be \>32. In this case, as shown in the right panel of [Table 1](#T1){ref-type="table"}, the false positive rate is close to zero yet the false negative rate is much smaller than for the IUT. The second row of [Table 1](#T1){ref-type="table"} presents the situation where one tissue has the same expression level as the target, and the other expression levels are smaller than the expression level of the target tissue. As elaborated in the previous section for the Bayesian approach, expression levels equal to the expression level of the target tissue are neither evidence in favor nor against the hypothesis of interest. This is reflected by an increased rate of genes detected as selectively overexpressed for both the IUT and Bayes factor. Taking 32 as a demarcation value for the Bayes factor yields 30% of the genes detected as selectively overexpressed. In case that the pair of tissues cannot be considered as a functionally equivalent group, these are false positives and avoiding them can be solved by taking a much higher Bayes factor (e.g. log~2~ = 10, see [Fig. 1](#F1){ref-type="fig"}B) as a demarcation value. Then, also the Bayesian procedure becomes conservative. Note that adding more tissues with an expression level equal to the target tissue, will quickly reduce the proportion supported to almost zero (e.g. with two tissues having the same expression as the target, the 0.30 drops to 0.16). As illustrated in [Table 1](#T1){ref-type="table"}, this holds also for a lower effect size (δ = 0.5*s*) for the tissues that support the hypothesis *H*~1~. The fourth row shows that the performance of both the IUT and the Bayes factor is rather good if there is no support at all for the hypothesis of interest.

To illustrate that the Bayesian procedure is more informative than reporting the largest *P*-value of the partial tests involved in the IUT, we simulated data for which one tissue has the same mean as the target tissue (7.3). The means of the remaining tissues steadily varied from 7.3 to 7.3 − 3*s* = 7.3 − 0.12 (corresponding to an effect size that varies from 0 to 3), this is increasingly supporting the hypothesis of selective overexpression in the target tissue. For each effect size, 50 replicates (genes) were generated. A scatterplot for the IUT is depicted in [Figure 2](#F2){ref-type="fig"}A, where the largest *P*-value of the partial tests is plotted against the effect size for the IUT; a scatterplot for the Bayesian procedure is depicted in [Figure 2](#F2){ref-type="fig"}B where the log of the Bayes factor is plotted against this same effect size. Clearly, the Bayesian procedure detects that the support of the 20 tissues increases, while this information is not captured by the IUT. Fig. 2.Scatter plots for the largest *P*-value of the IUT (**A**) and of the log~2~ Bayes factors (**B**) in function of the effect size.

Advantages of the IUT over the Bayesian approach are that it is less computationally intensive and has a clear cutoff. First, running the simulation discussed above on an Intel Core Duo took less than a second for the IUT and less than 10 min for the Bayesian approach (with 5000 iterations): this is for all eight conditions and with 5000 replications per condition (in practice, this corresponds to eight analyses of 5000 genes). Note that although the Bayesian procedure is much slower, the time required for the analysis of a large dataset using an ordinary desktop is still very reasonable. Second, the conventional use of 0.01 or 0.05 as a cutoff for significance gives a clear rule. For the Bayes factor, there is not such a clear rule: Choosing a cutoff that yields a good balance between the number of true and false positives (this is not too conservative nor too liberal) depends on the number of tissues, their number of replicates and their effect sizes. Therefore, a simulation study should be performed prior to the analysis of the intended data; as an aid for potential users, we provided the script file of our simulation.

3.2 Tissue-selective genes {#SEC3.2}
--------------------------

We used a publicly available microarray dataset (<http://www.ncbi.nlm.nih.gov/geo/>, accession number GSE9954; see also Thorrez *et al.*, [@B21]) that we generated via Affymetrix mRNA expression analysis using 430 2.0 arrays. This database consists of 22 different murine tissues, with 3--5 replicates for each tissue. Note that in the Bayesian procedure, the replications are supposed to follow a normal distribution; therefore, we took the log~2~ of the RMA preprocessed expression data.

For each tissue, the Bayesian procedure was used to find genes preferentially expressed in a particular tissue. We decided that a gene is tissue-selective upregulated when the Bayes factor was \>32 on all probesets matching the gene. Genes that are tissue-selective are expected to be associated with the cellular processes which are the characteristic for the tissue. To assess whether this was the case for the gene sets identified by the Bayesian procedure, we tested functional overrepresentation of these genes using Ingenuity Pathway Analysis 7.1. The five most significant functions and diseases per tissue are listed in [Table 2](#T2){ref-type="table"}. It is apparent that most of these clearly reflect tissue-specific functions. This indicates that the underlying gene sets truly capture the tissue selectivity. For seminal vesicle only two functions reached significance and for salivary gland no significant function was found. Probably, this is due to the fact that these two tissues are studied by few researchers, leading to few publications on which Ingenuity Pathway Analysis can base its results. Table 2.For each tissue, the genes identified by the Bayesian procedure to be tissue-selective were analyzed for functional overrepresentation![](btp439i11.jpg)[^3]

It is important to realize that the obtained results depend strongly on the panel of tissues considered. Including more tissues will lead to a smaller number of genes denoted to be tissue-selective by the Bayesian procedure, but the biological specificity for these genes will be higher. For example, the panel used here contains three contractile tissues: gastrocnemius, diaphragm and heart; especially gastrocnemius and diaphragm have rather similar functions. Therefore, the number of tissue-selective genes is small (e.g. for gastrocnemius only 132 genes were found; see [Table 2](#T2){ref-type="table"}) and their functions are very specific (e.g. quantity of skeletal muscle associated to gastrocnemius and rib formation to diaphragm; see [Table 2](#T2){ref-type="table"}).

4 DISCUSSION {#SEC4}
============

Finding tissue-selective genes is a recurring biological theme. As shown, the use of procedures that correct for multiple testing associated to the comparison of all target tissue--other tissue pairs is erroneous. A correct statistical procedure is the IUT. However, it is conservative and limited in information. As an alternative, we proposed a Bayesian procedure. In a simulation study, it was shown that this procedure is in most situations less conservative, while still keeping the number of false positives acceptable. Also, it is more informative than the IUT because it expresses how strongly the complete expression profile supports the hypothesis of tissue selectivity. Note that although we discussed the case of selective overexpression, both methods can also be used to find selective underexpressed genes.

The results of both the IUT and Bayesian procedure are highly dependent on the panel of tissues considered. These methods denote a gene as preferentially expressed in a particular tissue when expression in the tissue is higher than in each of the other tissues considered in the panel. Small panels can be expected to lead to large lists of tissue-selective genes containing many genes that are even more selectively overexpressed in a tissue not included in the panel. In an application of the Bayesian procedure to a panel of 22 tissues, we illustrated this by including two tissues with rather similar functionality, namely gastrocnemius and diaphragm. To avoid biologically flawed results, the proposed Bayesian method as well as the IUT should be applied with careful consideration of the tissues to include in the panel.

The use of the Bayesian procedure and the IUT is not limited to finding tissue-selective genes in normal tissues. Any problem involving the comparison of a reference group to each of the other groups (more than two) can be envisaged. Interesting applications are the comparison of normal tissue (persons) to several types of diseased tissue (persons). For example, Nishimura *et al.* ([@B17]) aimed at genes susceptible of autism by comparing normal persons to each of two groups of autistic persons.

An advantage of the Bayesian approach is that it is flexible in the kind of hypotheses that can be tested with it. Not only can it be easily adapted to test the hypothesis *H*~1~ of selective expression in a few (and not a single) tissue against the complement *H*~2~: not *H*~1~, but also against more specific alternative hypotheses *H*~2~. For example, it may be of interest to know whether the data support that a particular gene is upregulated in a very specific tissue belonging to a group of related tissues (e.g. three neuronal tissues) rather than that it is upregulated overall in this group of related tissues . The procedure that was proposed here is general and can thus be easily adapted to test such hypotheses. On the other hand, the IUT always tests against *H*~2~: not *H*~1~. A more challenging adaptation of the Bayesian procedure would be the possibility to include equalities in the hypothesis (e.g. to find categorical tissue-specific genes) in a way that the procedure is efficient enough to deal with thousands of genes \[see Klugkist and Hoijtink ([@B14]) for a discussion of Bayes factors for equality and inequality constrained hypotheses\]. Inclusion of such equality constraints for the IUT are discussed by Tuke *et al.* ([@B22]) (an equivalence testing approach is used).

^1^Bayes factors below 0.0001 were set equal to 0.0001, while Bayes factors over 10 000 were set equal to 10 000.

^2^This number drops to 0 when accounting for the multiple testing associated to the testing of 5000 genes (results not shown).
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[^2]: Different panels correspond to different decision rules: a gene is declared tissue-selectively over-expressed (hypothesis *H*~1~) in the first panel, if the IUT rejects *H*~0~ against *H*~1~; in the second panel, if the Bayes factor \>1; and in the third panel, if the Bayes factor \>32. The different rows correspond to different amounts of support of *H*~1~, while the different columns of each panel correspond to different effect sizes.

[^3]: From left to right, the different columns contain the tissue label (Tissue); the number of genes found to be tissue-selective (Nr BF); the number mapped to the pathway (Nr IPA); their five most significant functions and diseases (Top-5 functions enriched in gene set); and the significance of the functions and diseases obtained with the Benjamini--Hochberg corrected Fisher\'s exact test (Significance).
